[go: up one dir, main page]

GB2173798A - Cephalosporanic acid derivatives - Google Patents

Cephalosporanic acid derivatives Download PDF

Info

Publication number
GB2173798A
GB2173798A GB08609661A GB8609661A GB2173798A GB 2173798 A GB2173798 A GB 2173798A GB 08609661 A GB08609661 A GB 08609661A GB 8609661 A GB8609661 A GB 8609661A GB 2173798 A GB2173798 A GB 2173798A
Authority
GB
United Kingdom
Prior art keywords
compound
cephem
amino
lithium
propen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08609661A
Other versions
GB2173798B (en
GB8609661D0 (en
Inventor
Hideaki Hoshi
Jun Okumura
Yoshio Abe
Takayuki Naito
Shimpei Aburaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of GB8609661D0 publication Critical patent/GB8609661D0/en
Publication of GB2173798A publication Critical patent/GB2173798A/en
Priority to MYPI87002270A priority Critical patent/MY100694A/en
Application granted granted Critical
Publication of GB2173798B publication Critical patent/GB2173798B/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/187-Aminocephalosporanic or substituted 7-aminocephalosporanic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/227-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

This invention provides novel cephalosporin intermediates, 7 beta -amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carboxylic acid and esters thereof having the general formula <IMAGE> wherein the configuration of the 3-propenyl group is Z sometimes referred to as cis- and R is hydrogen or a conventional carboxy-protecting group, and acid addition salts thereof and the metal salts of the foregoing substance wherein R is hydrogen. These compounds are useful as intermediates for preparation of orally active cephalosporins. <IMAGE>

Description

SPECIFICATION Cephalosphoranic acid derivatives This application relates to 7-amino-3-propenyl cephalosporanic acid and esters thereof.
Description of the prior art U.K. Patent Specification 1,342,241 published January 3, 1974 (corresponding U.S. Patent Nos.
3,769,277, and 3,994,884, granted October 30, 1973, and November 30, 1976) discloses the Compound VI but there is no description of 7-amino-3-[(Z)-1-prnpen-1-yI]-3-cephem-4-carboxyIic acid as an intermediate in the preparation thereof.
U.S. Patent No. 4,409,214 patented October 11, 1983 discloses the preparation of Compound VII via the Wittig reaction on diphenylmethyl 7-benzylideneamino-3-triphenyl-phosphoniomethylceph-3-em-4-car- boxylate in Preparations 38 and 39, but there is no description of 7(3-amino-3-[(Z)-1-prnpen-1-ylj-3-ce- phem-4-carboxylic acid, or of an other 3-(1-propen-1-yl)cephalosporin compound.
U.S. Patent No. 4,110,534 patented April 29, 1978 is particularly concerned with preparation of compounds such as VI and VII by the Wittig reaction. Refer particularly to columns 8, 9, and 49 (Example 21).
H. O. House et al. Jour. Org. Chem. 29, 3327-3333 (1964) have studied the effect of solvents and additives including lithium salts on the proportions of cis- and trans- olefins produced in the Wittig reaction with aldehydes.
Summary of the invention This invention relates to cephalosporin intermediates having Formula I, the synthetically useful acid addition and metal salts thereof, and to processes for their preparation.
In the compounds of Formula I, the configuration of the 3-propenyl group is Z- or cis-. R is hydrogen or a conventional carboxy-protecting group. The latter expression refers to protecting group of the sort conventionally used for amino or carboxyl groups in the synthesis of cephalosporin compounds. Suitable carboxyl protecting groups include aralkyl groups such as benzyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, and diphenylmethyl (benzhydryl), alkyl groups such as t-butyl; haloalkyl groups such as 2,2,2trichloroethyl, alkenyl groups such as allyl, 2-chloroallyl, alkoxymethyl groups such as methoxymethyl, 2 (trimethylsilyl)ethyl, trimethylsilyl, tert.-butyldimethylsilyl, tert.-butyldiphenylsilyl, and other carboxyl protecting groups described in the literature, for instance, in British Specification 1,399,086.We prefer to utilize carboxyl-protecting groups which are readily removed by treatment with acid, particularly benzhydryl or t-butyl. The acid addition salts and the metal salts of the foregoing substance where R is hydrogen are also part of the present invention.
The Z-, or cis- configuration of the 3-propenyl group is a critical aspect of the present compounds. This is the characteristic which determines the advantageous Gram negative antibacterial properties of the cephalosporin end products which are the subject of the parent application Serial No. 564,604.
The synthetically useful acid addition salts include the salts of Formula I with mineral acids such as hydrochloric acid, sulfuric acid and phosphoric acid, with organic sulfonic acids such as p-toluenesulfonic acid and other acids known and used in the cephalosporin arts.
Those substances of Formula I wherein R is hydrogen also form metal salts. Synthetically suitable metal salts include the sodium, potassium, calcium, magnesium, aluminum, and zinc salts.
The most preferred compounds of the invention are: 1. Diphenylmethyl 7ss-amino-3-[(Z)-1 -propen-1 -yl]-3-cephem-4-carboxylate.
2. Diphenylmethyl 7p-amino-3-[(Z)-l-propen-l -yl]-3-cephem-4-carboxylate hydrochloride.
3. Dip henylmethyl 7p-a mino-3-[(Z)- 1 pen-I -yl]-3-cephem-4-carboxylate sulfate.
4. Sodium 7t3-amino-3-[(Z)-1-propen-1-yIi-3-cephem-4-carboxylate.
5. Potassium 7ss-am ino-3-[(Z)-1 -propen-1 -yl]-3-cephem-4-carboxylate.
6. 7ss-Amino-3-[(Z)-1 -propen-1-yl]-3-cepehm-4-carboxylic acid.
Detailed description of the invention In another aspect, this invention relates to processes for the preparation of the compounds of Formula I. Preferred procedures are shown in Reaction Schemes 1 and 2.
In reaction Scheme 1, the diphenylmethyl group is shown as the preferred carboxy-protecting group. It will be appreciated by those skilled in the art that other carboxyl-protecting groups, well-known in the art, may be used.
In the Wittig reaction of Compound III with acetaldehyde, we have found that addition of an appropriate lithium halide such as lithium chloride, lithium bromide or lithium iodide improves the yield and proportion of UE isomer of the reaction product Ila. The reaction is preferably carried out with 5 to 15 chemical equivalents, preferably 10 equivalents of lithium bromide.
Methylene chloride is the preferred reaction medium preferably containing a cosolvent such as dimethylformamide or isopropanol in minor proportions of from about 1/10 to 1/3 part by volume per part of methylene chloride. Reaction temperatures in the range of -10 C to +25"C are appropriate with 0 to 25"C being preferred. The Wittig product Ila is extracted into a suitable organic solvent such as ethyl acetate and the extract is treated with Girard's reagent T to afford the 7-aminoceph-3-em compound of the present invention, la. Refer to Procedure 3 hereof. Subsequent treatment of la with trifluoroacetic acid (TFA) yields 7ss-amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carboxylic acid (Ib, Procedure 7) in the ratio of Z/E = 9/1.Acylation of Ib with p-hydroxyphenylglycine by a conventional acid chloride method or an activated ester method yields the orally effective cephalosporin V of the parent application Serial No.
564,604.
An alternative route, acylation of 7ss-amino-3-propen-1-yi cephalosporin ester la with the N-BOC (tert.butoxycarbonyl) blocked p-hydroxyphenylglycine in the presence of DCC (dicyclohexylcarbodiimide) and followed by deblocking with TFA (trifluoroacetic acid) also yields the cephalosporin V.
Scheme 1 Scheme 2 PhcE=N0}JLS=PPh3 PhcH2coNHy7 S CH=PPh3 COOCHPh2 III O COOCHPh2 COOCHPh2 Procedure 3 | 10 VIII Procedure 10 PhCII= pC::ICBCal I PhCH2CONH S t F N < CH=CH-CH3 J v4 CH=CHCH3 - COOCHPh2 ITa 0 COOCHPh2 COOCHPhZ Procedure 3 aProcedure 11 Ix Y \L H2 CH=CBiCR3 COOCHPhZ Procedure 5 COOCHPh2 / \ Procedure 7, or 8 Ia Procedure 7, or 8 HO C1HCONH H2N NHBOC HzCH=CH-CH3 P < CH=CH-CH3 Iv coOcHPh2 COOR Tb Procedure 6 , 'Yrocecure 9 \ Procedure 9 HO 5 CHCONEL O < H=CH-CH3 V COOH
BMY-28100 Description of specific embodiments The following abbreviations which appear in the experimental procedures have the meaning indicated below: Ph = phenyl BOC = COOC(CHs)3 DCC = dicyclohexylcarbodiimide TFA = trifluoroacetic acid EtOAc = ethyl acetate DMF = dimethylformamide Procedure 1 Diphenylmethyl 7-benzylideneamino-3-triphenylphosphoniomethyl-3-cephem-4-carboxyjate chloride To a suspension of diphenylmethyl 7-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride (200 g, 0.44 mole) in CH2CI2 (940 ml) was added 1 N NaOH (440 ml) at room temperature. The mixture was shaken for 10 minutes and the organic layer was separated. To this organic layer were added MgSO4 (75 g) and benzaldehyde (51 g), 0.48 mole) and the mixture was allowed to stand for 3 hours at room temperature. The reaction mixture was filtered and the insolubles were washed with CH2CI2 (200 ml). To the combined filtrate and washings was added triphenylphosphine (126 g, 0.48 mole). The mixture was con centrated to about 400 ml under reduced pressure and allowed to stand for 4 days. The resulting viscous oil was diluted with ethyl acetate (1 I) and triturated to separate the title compound, a pale yellow crystalline powder which was collected by filtration and dried in vacuo Yield 322 g (96%). M.p. 1851900C (dec.).
IR: vmsarx cm-1 1780, 1720, 1630.
UV: #maxCH2Cl2 nm () 260 (24100).
Procedure 2 Diphenylmethyl 7-benzylideneamino-3-[(triphenylphosphoranylidene)-methyl]-3-cephem-4-carboxy- late (III) A mixture of diphenylmethyl 7-benzylideneamino-3-triphenylphosphoniomethyl-3-cephem-4-carboxy- late chloride (322 g, 0.42 mole) and 5 N Na2CO3 (252 ml) in CH2C12 (1.6 I) was stirred vigorously for 15 minutes at room temperature. The organic layer was separated, dried over MgSO4 and concentrated to about 500 ml of volume. The concentrate was diluted with acetone (1 I), with stirring, to give a light yellow crystalline powder which was collected by filtration to yield 237 g (78%) of 3, melting at 195~198 C (dec.).
IR: V,,KBj cm 1 1770, 1620.
UV: XCH2sCI2 n m (E) 254 (23000), 389 (22000).
NMR: bcDc13 ppm 2.56 & 3.16 (2H, ABq), 5.00 (1H, d, J=4 Hz), 5.23 (1H, d, J=4 Hz), 5.47 (1H, d, J=22 Hz), 6.95 (1H, s), 7.2-7.8 (30H, m), 8.55 (1H, s).
Procedure 3 Diphenylmethyl 7-amino-3-((Z)- 7-propen- l-yl)-3-cephem-4-carboxylate hydrochloride (la hydrochloride) To a cold solution of LiBr (19 g, 216 m moles) in a mixed solvent of dry dimethylformamide (100 ml) and CH2CI2 (300 ml) were added acetaldehyde (20 ml, 360 m moles) and diphenylmethyl 7-benzylide neamino-3-[(triphenylphosporanylidene)methyl]-3-cephem-4-carboxylate (III) (15 g, 20 m moles) at -5"C.
The mixture was allowed to stand for 20 hours at -5~-10 C and then 5 hours at room temperature. The resulting light brown solution was concentrated at ca. 100 ml of volume in vacuo and added to a two layer solvent of ethyl acetate (400 ml) and H2O (400 ml). The upper layer was separated and diluted with isopropyl ether (400 ml). Silica gel (Wako gel C-100, 40 g) was added to the mixture. The mixture was shaken for 5 minutes and filtered through a pad of diatomaceous filter aid. Insolubles were washed with a mixed solvent of ethyl acetate-isopropyl ether (1/1, 200 ml). The combined filtrate and washings were concentrated to ca. 400 ml of volume. A 0.5 M Girard reagent T solution in methanol (60 ml) and acetic acid 96 ml) was added to the above concentrate and the mixture was stirred for 15 minutes at room temperature.The mixture was evaporated to ca. 200 ml of volume, washed with H2O (200 ml), sat. aq.
NaHCO3 (3x20 ml) and brine (20 ml) successively, dried over MgSO4, treated with charcoal and concentrated to ca. 50 ml. To the concentrate was added N HCI in methanol (40 ml) at room temperature and left standing for 15 minutes. The mixture was evaporated to ca. 30 ml and diluted by addition of ether i300 ml). The precipitate was collected by filtration and dried over P205 to give 7.9 g of light yellow powder. A solution of the powder (7.3 g) in a mixed solvent of methanol (80 ml) and ethyl acetate (80 ml) was treated with charcoal, concentrated to ca. 100 ml, seeded with crystalline hydrochloride of the title compound, diluted slowly with ether (80 ml) and stirred for 1 hour. The separated colorless crystals were collected by filtration and dried over P205 in vacuo to give 6.3 g (71%) of the title compound.This product is a mixture of the isomers Z and E with reference to the propenyl moiety at the 3 position (Z/E=9/1 by HPLC) (Lichrosorb RP-18, 80% CH3OH-pH 7.2 phosphate buffer, 254 nm, 1 ml/min.).
IR: VK3,' cm-l 2850, 1785, 1725.
UR: Xma ZH nm (E I,) 287 (173).
NMR: cDMs ds ppm 1.47 (27/10H, d-d, J=7, 2 Hz, =CHCH3, cis, 1.74 (3/10H, d, J=7 Hz, =CHCH3, trans), 3.47 & 3.8 (each 1H, d, J=16 Hz), 5.13 1H, d, J=4.5 Hz, 6-H), 5.23 (1H, d, J=4.5 Hz, 7-H), 5.62 (1H, d-q, J=10 & BR< 7 Hz, 3-CH=CH), 6.24 (1H, d-d J=10 & 2 Hz, 3-CH), 6.81 (1H, s, CHPH2), 7.35 (10H, m, Ph-H).
Procedure 4 Diphen ylmethyl 7-amino-3-((Z)- 1-propen- 1-yl)-3-cephem-4-carboxylate (Ia) To a stirred suspension of the hydrochloride of diphenylmethyl 7-amino-3-((Z)-1-propen-1-yl)-3-cephem4-carboxylate (5 g, 11.3 m moles) in H2O (20 mol) and ethyl acetate (40 ml) was added NaHCO3 until the pH of the mixture became 8. The organic layer was washed with sat. aq. NaCI (5 ml), dried over MgSO4 and concentrated to ca. 20 ml of volume. The resulting solution was diluted with isopropyl ether (10 ml) and seeded with crystalline la. Additional isopropyl ether (30 ml) was added slowly to the mixture with stirring.After 15 minutes the separated colorless crystals were collected by filtration, washed with isopropyl ether (10 ml) and dried over P2Os in vacuo to give 4.3 g (94%) of the title compound (Z/E=9/1 by HPLC) (Lichrosorb RP-18 80% methanol - pH 7.2 phosphate buffer, 254 nm, 1 ml/min).
IR: vmsarx cm- 3450, 1765, 1730.
UV: Am H nm (E:,) 289 (185).
NMR: bcDc13 ppm 1.43 (3H, d-d, J=2 & 7 Hz, CH=CHCH3), 1.66 (2H, br, s, disappeared by D2O, NH2), 3.23 & BR< 3.55 (each 1H, d, J=17 Hz, 2-H), 4.73 (1H, d, J=4.5 Hz, 6-H), 4.96 (1H, d, J=4.5 Hz, 7-H), 5.46 (1H, d-q, J=10 & 7 Hz, 3-CH=CH), 6.06 (1H, br, d, J=10 Hz, 3-CH), 6.94 (1H, s, CHPh2), 7.3 (10H, m, Ph-H).
Procedure 5 Diphenylmethyl 7-l(D)-a-(t-butoxycarbonylamino)-a (4-hydroxyphenyl)acetamidoj.3-((Z)- 1-propen- 1-yl)-3- cephem-4-carboxylate (IV) A mixture of diphenylmethyl 7-amino-3-((Z)-1-propen-1-yI)-3-cephem-4-carboxylate (la) (4.2 g, 10.4 m moles), (D)-of-(t-butoxycarbonylamino)-a-(4-hydroxyphenyl)acetic acid (3.3 g, 12.5 m moles) and DCC (2.6 g, 12.5 m moles) in ethyl acetate (104 ml) was stirred for 1.5 hours at room temperature. The mixture was filtered and insolubles were washed with ethyl acetate (10 ml). The filtrate and the washings were combined and washed with sat. aq. NaHCO2 (3x5 ml), brine (5 ml), 10% HCI (5 ml) and brine successively, dried over MgSO4, treated with charcoal and filtered.The filtrate was concentrated to ca. 10 ml and diluted with n-heptane (20 ml). The precipitate was collected by filtration and dried over P205 in vacuo. Yield 7.8 g (90% pure, quantitative in weight) as colorless powder (Z/E=9/1 based on HPLC) (Lichrosorb RP-18, 80% methanol-pH 7.2 phosphate buffer, 254 nm, 1 ml/min.).
IR: vmsarx cm- 3400, 1790, 1720, 1690.
UV: XE nm (E 1yam) 278 (113), 289 (115), 295 (95).
NMR: bcDc13 ppm 1.3-1.45 (12H), m, BOC-H & =CH-CH3), 3.08 & 3.33 (each 1H, d, J=18 Hz, 2-H), 4.92 (1H, d, J=4.5 Hz, 6-H), 5.06 (1H, d, J=6 Hz. by D2O, CHN), 5.5 (1H, d-q, J=10 & 7 Hz, 3-CH=CH), 5.68 (1H, d-d, J=4.5 & Hz. d, J=4.5 Hz by D2O,7-H), 6.01 (1H, d,J=10 Hz, 3-CH), 6.65 & .08 (each 2H, d,J=8 Hz, 6.71 (1H, d, J=8 Hz, disappered by D2O, 7-NH2). 6.88 (1H, s, CHPh2), 7.3 (10H, m, Ph-H).
Procedure 6 BM Y-28 100; 7-[(D)-2-amino-2-(4-hydroxyphenyl)acetamido]-3-(propen-1-yl)-3-cephem-4-carboxylic acid (V) A mixture of diphenylmethyl 7-[(D)-(t-butoxycarbonylamino)-(4-hydrnxyphenyl)acetamidoj-3-((Z)-1 propen-1-yl-3-cephem-4-carboxylate (IV) which was prepared in Procedure 5 (90% pure, 7.7 g, 10.6 m moles), anisole (7.7 ml) and trifluoroacetic acid (77 ml) was stirred for 1 hour at room temperature. The mixture was concentrated in vacuo. Toluene (50 ml) was added to the concentrate and the mixture was evaporated in vacuo. Ether (200 ml) was added to the residual oil. The separated solid was collected by filtration, washed with ether (20 ml) and dried over KOH in vacuo to afford 5.3 g of trifluoroacetic acid (TFA) salt of BMY-28100.The salt (5.3 g) was dissolved in H2O (100 ml), treated with charcoal and placed on a column packed with Diaion HP-20 (0.6 I). The column was washed with H2O (4 I) and eluted with 40% aqueous MeOH. The methanolic fractions (1.7 I) containing the desired product were collected and evaporated to ca. 20 ml of volume. The concentrate was diluted slowly with acetone (100 ml). The separated colorless crystalline powder was collected by filtration, washed with acetone (20 ml) and dried over P205 in vacuo to give 4 g (97%) of BMY-28100 (Z/E=9/1, Zwitterion) (Lichrosorb RP-18, 20% methanol - pH 7.2 phosphate buffer, 254 nm, 1 ml/min.
Procedure 7 7-amino-3-f(Z)- 1-propen- 1-yllceph-3-em-4-carboxylic acid, I b To a stirred solution of 260 ml anisole and 1.38 1 of trifluoroacetic acid (TFA) cooled to 0 C was added 149.7 g (0.338 mole) of diphenylmethyl 7-amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carboxylic acid hydrochloride (0.338 mole, Procedure 3 or 11). The resulting slurry was then stirred at room temperature for 1 hour. Most excess of TFA was removed in vacuo on the rotary evaporation. The residual supernatant solution was decanted and the residual slurry was triturated with 1.5 1 of dry ether during 1 hour. The crystalline product was filtered and dried over P205 to give 87.24 g Ib trifluoroacetate.These 87.24 g of the trifluoroacetate were suspended and stirred into 900 ml of water (pH ca. 2.5). The mixture was cooled to +5"C and then adjusted to pH 0.6 with 12 N HCI. The yellow solution was charcoal treated and the slurry was filtered on a diatomaceous filter aid pad. The resulting solution was cooled to +5 C and the pH was adjusted to 2.0 with 20% NaOH. The suspension was kept 1 hour in a refrigerator to aid crystalli- zation. The crystals were collected, washed with 800 ml of water, 800 ml of acetone and vacuum dried at room temperature. Yield 69.4 g (85.5%). Contains 9.7% of trans isomer (determined by HPLC column RP18 MERCK; H2(NH4)PO4, 0.1 mole 95 ml + CH3 CN 5 ml; detected at 290 nm).
Procedure 8 7-amino-3-((Z)- itprnpen 1-yl)-3-cephem-4-carhoxylic acid, I b A solution of the phosphoranyl compound lil as produced by Procedure 2 (50.0 g, 68.7 m mole) in CH2Ci2 (500 ml) was mixed with a solution of lithium bromide (29.8 g), 343 m mole) in dry DMF (170 ml) containing a small amount of CH2CI2 (10 ml) and then with anhydrous acetaldehyde (39 ml, 687 m mole; prepared from paraldehyde and toluenesulfonic acid by distillation, according to the procedure of N.L.
Drake and G.B. Cook, Org. Syn. Col. Vol. II, p. 407). The mixture was placed in a sealed vessel and kept at 20"C for 2 days. The reaction mixture being evaporated, the residual liquid was diluted with EtOAc (800 ml), washed with water (3x300 ml) and a saturated NaCI solution (300 ml), and evaporated to give the blocked 3-propenyl solution (300 ml), and evaporated to give the block 3-propenyl derivative lla as foamy solid (34 g), which was used for the next reaction without further purification.
The crude Ila obtained above was treated with 98% formic acid (35 ml) and concentrated HCI (17 ml, 206 m mole) at room temperature for 1 hour. To the reaction mixture was added water (350 ml) to separate an oily layer, which was washed out with EtOAc (3x100 ml). The pH of the aqueous layer was adjusted to about 3 with 4N NaOH (ca. 65 ml) under stirring to give crystalline solid, which was collected by filtration and washed with water (50 ml) to afford the title compound (Ib, 9.7 g, 59%). HPLC [Lichrosorb RP-18, 4x300 mm, MeOH: phosphate buffer (pH 7) = 15 : 85] showed that this product was an 83:17 mixture of Z and E isomers about the double bond of the 3-propenyl group. M.p. 200"C (dec.).
IR: VmaX (KBr) in cm- 3420, 1805, 1620.
UV: Xma, (pH 7 phosphate buffer) in nm (E) 283 (8900).
PMR: 3 (D2O + NaHCO3) in ppm 1.69 and 1.88 (3H, each d, J=6.0 Hz, Z and E of -CH=CH-CH3), 3.38 and 3.72 (2H, Abq, J=17 Hz, H-2), 5.18 (1H, d, J,=5.0 Hz, H-6), 5.51 (1H, d, H-7), ca. 5.8 (1H, m, -CH=CH-CH3) and 6.06 (1H, d, J=11 Hz, -CH=CH-CH3).
Anal. Calcd. for C,oH12N203S: C, 49.44; H, 5.03; N, 11.66; S, 13.34%.
Found: C, 50.20; H, 4.94; N, 10.93; S, 12.82%.
Procedure 9 7-[rD)-2-amino-2-r4hydroxyphenyl)acetamido i-prop en- 1- 1-yl)-3-cephem-4-carboxylic acid, V Dimethylaniline (1.7 ml, 13.1 m mole), trimethylsilyl chloride (2.1 ml, 16.4 m mole) and triethylamine (TEA, 2.3 ml, 16.4 m mole) were added successivleyto a suspension of Ib produced by Procedure 8 (1.58 g, 6.56 m mole) in CH2C12 (16 ml) under ice-cooling. The mixture was stirred at room temperature for 30 minutes. To the mixture was added portionwise under stirring D-p-hydroxyphenylglycyl chloride hydrochloride (1.46 g 6.56 m mole) and the reaction was monitored by HPLC [Lichrosorb RP-18, 4x300 mm, MeOH: phosphate buffer (pH 7) = 25:75]. An additional amount of the glycyl chloride was added to the mixture 3 times at 15 minute intervals (291 mg each) to complete the acylation.After the addition of dry MeOH (2.0 ml) containing dry DMF (0.1 ml), the resulting clear solution was neutralized with TEA (3.2 ml) to pH 6 and then diluted with CH2CI2 (30 ml) to give a precipitate, which was collected by filtration and washed with CH2Cl2 (10 ml) to give the title compound as the dimethylformamide solvate (2.39 g, yield 94%; ca. 50% pure; Z/E = 47:12 by HPLC).
Procedure 10 Diphenylmethyl 7-phenylacetamido-3-((Z)-propen- 1-yl)ceph-3-em-4-carboxylate, IX
A stirred solution of 18 1 of CCI4, methanol and 12 g p-benzoyl benzoic acid was cooled to 8"C 970 ml of acetaldehyde were added. The temperature of the resulting solution rose to +14 C. After five minutes, 588 g (0.7749 mole) of diphenylmethyl 7-phenylacetamido-3-[(triphenylphoranylidene)methyl]-3-cephem- 4-carboxylate was added. The cooling bath was removed and the mixture vigorously stirred for 4 hours at 35"C shaded from light under an N2 atmosphere until complete dissolution of the phosphorane had occurred.
The resulting solution was vacuum concentrated and the residue was dissolved in 2 1 of ethanol, and the solution was vacuum concentrated to a semi-crystallized residue which was slurried with 3 1 of ethanol.
The mixture was stirred for 2 hours at +5 C and let stand overnight, crystals were collected twice, washed with ethanol, and vacuum dried at room temperature. Yield 191 g (47%). M.p. 124-128 C contains 7.5% of trans isomer (determined by HPLC column Lichrosorb Si 60 5 iim Merck eluted with 85% toluene, 15% ethyl acetate.
Procedure ii Diphenylmethyl 7-amino-3-r6Z)-propen-1-yl)ceph-3-em-4carboxylate hydrochloride, la To a stirred solution of 159.7 g (0.767 mole) of PCI5 in 2.8 I CH2CI2 were added 56.7 ml (0.700 mole) of pyridine in 280 ml CH2CI2 over a 20 minute period. Under a nitrogen atmosphere the slurry was cooled to 2"C while 256 g of IX produced by Procedure 10 (0.488 mole) was added.The mixture was stirred for 40 minutes and the resulting slurry was poured rapidly into a vigorously stirred solution of 1.4 1 of CH2CI2, and 209 ml (2.33 moles) of 1,3-butanediol at -20 C, so that the temperature did not rise above -5 C. The cooling bath was removed and after 45 minutes the temperature rose to 10"C and was held there for 35 minutes. Water (1.0 liter) was added and stirring continued for 5 minutes after which the layers were allowed to separate. The organic layer was washed with 600 ml HCI 2N and then 400 ml saturated brine.
The combined aqueous extracts were back-washed with 2 x 600 ml of CH2CI2 and combined with the original CH2CI2 extract.
The solution was dried over anhydrous MgSO4. The MgSO4 slurry was filtered and the MgSO4 washed with 2 x 500 ml CH2C12. The combined filtrates were concentrated in vacuo on the rotary evaporator to a volume of 2.4 liters and diluted with 2.5 liters of ethyl acetate. The solution was concentrated again to a volume of ca. 1.3 liters. The resulting crystal - slurry was filtered, washed with 3 x 300 ml ethyl acetate.
After air and vacuum drying over P2Os there was obtained 149.8 g of the title compound as beige crystals. Yield 69.3%.

Claims (13)

1. A compound of the formula
wherein the 3-propenyl group has the Z-configuration and R is hydrogen or a conventional carboxy-protecting group, and acid addition salts thereof and metal salts of the foregoing substance wherein R is hydrogen.
2. The compound of Claim 1 wherein R is a group selected from hydrogen, methoxymethyl, 2,2,2 trichloroethyl, 2-(trimethylsilyl)ethyl, t-butyl, benzyl, diphenylmethyl, o-nitrobenzyl, p-nitrobenzyl, trimethylsilyl, t-butyldimethyl-silyl, t-butyldiphenylsilyl, allyl, and 2-chloroallyl and acid addition salts thereof.
3. The compound of claim 1 or 2 wherein the acid addition salt is selected from of hydrochloride, sulfate, p-toluenesulfate, and phosphate.
4. The compound of Claim 1 or 2 wherein the metal salt is sodium, potassium, calcium, or aluminum salt.
5. The compound of Claim 2 which is diphenylmethyl 7(3-amino-3-[(Z)-1-prnpen-1-ylj-3-cephem-4-car boxylate and the hydrochloride thereof.
6. The compound of Claim 2 which is 7ss-amino-3-[(Z)-1-propen-1-yl]-3-cephem-4-carboxylic acid and the hydrochloride thereof.
7. The compound of Claim 4 which is sodium 7P-amino-3-[(Z)-l -propen-l -yl]-3-cephem-4-carboxylate.
8. The process for preparing a compound as claimed in Claim 1 which comprises reacting the intermediate of the formula
wherein R has the same meaning as in Claim 1, Ph is the phenyl group, with acetaldehyde in an inert organic reaction medium comprising dichloromethane, N, N'-dimethylformamide, isopropanol or a mixture thereof at a reaction temperature between 0 C and 25"C to provide a compound of the formula
and thereafter removing the benzylidene group or both the benzylidene group and the carboxy-protecting group and, if desired, separating the 3-(Z) and 3-(E) isomers to provide the compound of the formula
wherein R has the same meaning as in Claim 1.
9. The process of Claim 8 wherein the reaction with acetaldehyde is carried out in the presence of a lithium halide.
10. The process of Claim 9 wherein the lithium halide is lithium chloride, lithium bromide, or lithium iodide.
11. The process of Claim 9 wherein the lithium halide is lithium bromide.
12. A process as claimed in claim 8, substantially as described in the foregoing Experimental Procedures section.
13. A compound as claimed in claim 1, prepared by a process as claimed in claim 8, 9, 10, 11 or 12.
GB08609661A 1985-04-22 1986-04-21 Cephalosporanic acid derivatives Expired GB2173798B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI87002270A MY100694A (en) 1985-04-22 1987-09-29 Cephalosporanic acid derivatives.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72587185A 1985-04-22 1985-04-22

Publications (3)

Publication Number Publication Date
GB8609661D0 GB8609661D0 (en) 1986-05-29
GB2173798A true GB2173798A (en) 1986-10-22
GB2173798B GB2173798B (en) 1988-11-30

Family

ID=24916301

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08609661A Expired GB2173798B (en) 1985-04-22 1986-04-21 Cephalosporanic acid derivatives

Country Status (38)

Country Link
JP (1) JPS61249989A (en)
KR (1) KR860008189A (en)
CN (1) CN1015714B (en)
AR (1) AR242581A1 (en)
AT (1) AT392072B (en)
AU (1) AU589170B2 (en)
BE (1) BE904646A (en)
CA (1) CA1273629A (en)
CH (1) CH671399A5 (en)
CS (1) CS270435B2 (en)
CY (1) CY1571A (en)
DD (1) DD244557A5 (en)
DE (1) DE3613365A1 (en)
DK (1) DK163584C (en)
EG (1) EG18001A (en)
ES (1) ES8800236A1 (en)
FI (1) FI84268C (en)
FR (1) FR2580652B1 (en)
GB (1) GB2173798B (en)
GR (1) GR861065B (en)
HK (1) HK106290A (en)
HU (1) HU195223B (en)
IE (1) IE59014B1 (en)
IT (1) IT1228241B (en)
LU (1) LU86402A1 (en)
MY (1) MY100694A (en)
NL (1) NL192205C (en)
NO (1) NO164659C (en)
NZ (1) NZ215717A (en)
OA (1) OA08245A (en)
PT (1) PT82436B (en)
SE (1) SE500217C2 (en)
SG (1) SG90890G (en)
SU (1) SU1435155A3 (en)
YU (1) YU43697B (en)
ZA (1) ZA862985B (en)
ZM (1) ZM4286A1 (en)
ZW (1) ZW9086A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421219A3 (en) * 1989-10-03 1992-05-13 Bayer Ag Process for the preparation of 7-amino-3-((z)-1-propenyl-1-yl)-3-cephem-4-carboxylic acid
EP0503453A3 (en) * 1991-03-08 1992-12-09 Biochemie Gesellschaft M.B.H. New process for the production of cephalosporines and novel intermediates in this process
WO1993016084A1 (en) * 1992-02-05 1993-08-19 Biochemie Gesellschaft M.B.H. Process for the purification of a 3-cephem-4-carboxylic acid derivative
EP0634415A2 (en) * 1993-07-14 1995-01-18 Sumitomo Chemical Company, Limited Cephem compound, its production and its use for producing cephem antibiotics
AT399876B (en) * 1992-02-05 1995-08-25 Biochemie Gmbh Purificn. of 7-amino-3-((z)-1-propen-1-yl)-3 -cephem-4-carboxylic acid - useful in prodn. of broadband antibiotics
WO2004033464A1 (en) * 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Process for the preparation of (z)-isomer enriched 7-amino-3-propen-1-yl-3-cephem-4- carboxylic acid
WO2006048887A1 (en) * 2004-11-01 2006-05-11 Hetero Drugs Limited A novel process for preparation of cefprozil intermediate
US7544797B2 (en) 2003-10-30 2009-06-09 Cj Cheiljedang Corporation Processes for the preparation of cephem derivatives

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708955A (en) * 1985-06-24 1987-11-24 Bristol-Myers Company 3-(substituted)propenyl-7-aminothiazol-ylcephalosporanic acids and esters thereof
US4870168A (en) * 1987-02-26 1989-09-26 Bristol-Myers Company 3-Unsaturated alkyl cephems from 3-triflyl cephems
JP4046708B2 (en) * 2004-06-04 2008-02-13 明治製菓株式会社 Method for producing 3-alkenylcephem compound
CN103183686B (en) * 2011-12-30 2016-06-29 浙江新和成股份有限公司 The preparation method of 7 beta-amino-7 α-methoxyl group-3-cephem compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1342241A (en) * 1970-01-23 1974-01-03 Glaxo Lab Ltd Cephalosporin compounds
US4110534A (en) * 1970-01-23 1978-08-29 Glaxo Laboratories Limited Process for the preparation of 3-vinyl and substituted vinyl cephalosporins
US3769277A (en) * 1970-01-23 1973-10-30 Glaxo Lab Ltd Preparation of delta3-4 carboxy cephalosporins having a 3-vinyl or substituted 3-vinyl group
US4065620A (en) * 1971-06-14 1977-12-27 Eli Lilly And Company 3-(Substituted) vinyl cephalosporins
US4409214A (en) * 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4520022A (en) * 1983-01-28 1985-05-28 Bristol-Myers Company Substituted vinyl cephalosporins
AU566944B2 (en) * 1983-10-07 1987-11-05 Gist-Brocades N.V. Preparation of 3-cephem derivatives

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132419A (en) * 1989-10-03 1992-07-21 Bayer Aktiengesellschaft Process for the preparation of 7-amino-3-((z)-1-propen-1yl)-3-cephem-4-carboxylic acid
EP0421219A3 (en) * 1989-10-03 1992-05-13 Bayer Ag Process for the preparation of 7-amino-3-((z)-1-propenyl-1-yl)-3-cephem-4-carboxylic acid
EP0503453A3 (en) * 1991-03-08 1992-12-09 Biochemie Gesellschaft M.B.H. New process for the production of cephalosporines and novel intermediates in this process
EP1103555A1 (en) * 1992-02-05 2001-05-30 BIOCHEMIE Gesellschaft m.b.H. Process for the production of a 3-cephem-4-carboxylic acid derivative
WO1993016084A1 (en) * 1992-02-05 1993-08-19 Biochemie Gesellschaft M.B.H. Process for the purification of a 3-cephem-4-carboxylic acid derivative
AT399876B (en) * 1992-02-05 1995-08-25 Biochemie Gmbh Purificn. of 7-amino-3-((z)-1-propen-1-yl)-3 -cephem-4-carboxylic acid - useful in prodn. of broadband antibiotics
US5869648A (en) * 1992-02-05 1999-02-09 Biochemie Gesellschaft M.B.H. Process for the purification of a 3-cephem-4-carboxylic acid derivative
US6333409B1 (en) 1992-02-05 2001-12-25 Biochemie Gesellschaft M.B.H. Process for the purification of a 3-cephem-4-carboxylic acid derivative
EP1029864A1 (en) * 1992-02-05 2000-08-23 Biochemie GesmbH Process for the purification of a 3-cephem-4-carboxylic acid derivative
US6136967A (en) * 1992-02-05 2000-10-24 Biochemie Gesellschaft M.B.H. Process for the purification of a 3-cephem-4-carboxylic acid derivative
EP0634415A2 (en) * 1993-07-14 1995-01-18 Sumitomo Chemical Company, Limited Cephem compound, its production and its use for producing cephem antibiotics
US5969131A (en) * 1993-07-14 1999-10-19 Sumitomo Chemical Company, Limited Cephem compound, its production and its use for producing cephem antibiotics
WO2004033464A1 (en) * 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Process for the preparation of (z)-isomer enriched 7-amino-3-propen-1-yl-3-cephem-4- carboxylic acid
US7544797B2 (en) 2003-10-30 2009-06-09 Cj Cheiljedang Corporation Processes for the preparation of cephem derivatives
WO2006048887A1 (en) * 2004-11-01 2006-05-11 Hetero Drugs Limited A novel process for preparation of cefprozil intermediate
US7629482B2 (en) 2004-11-01 2009-12-08 Hetero Drugs Limited Process for preparation of cefprozil intermediate
EP2213676A1 (en) 2004-11-01 2010-08-04 Hetero Drugs Limited A Novel process for preparation of cefprozil

Also Published As

Publication number Publication date
NO164659C (en) 1990-10-31
NO861430L (en) 1986-10-23
DK163584B (en) 1992-03-16
DD244557A5 (en) 1987-04-08
CY1571A (en) 1991-12-20
DK182486A (en) 1986-10-23
CH671399A5 (en) 1989-08-31
SE500217C2 (en) 1994-05-09
NL8601011A (en) 1986-11-17
ES8800236A1 (en) 1987-10-16
JPH0327554B2 (en) 1991-04-16
FR2580652B1 (en) 1989-01-06
JPS61249989A (en) 1986-11-07
MY100694A (en) 1991-01-17
CA1273629A (en) 1990-09-04
DK163584C (en) 1992-08-10
FI861634L (en) 1986-10-23
NZ215717A (en) 1989-06-28
DE3613365A1 (en) 1987-01-02
HK106290A (en) 1990-12-28
YU65986A (en) 1987-12-31
NL192205B (en) 1996-11-01
PT82436A (en) 1986-05-01
IT8620162A0 (en) 1986-04-21
ATA106786A (en) 1990-07-15
YU43697B (en) 1989-10-31
BE904646A (en) 1986-10-21
AU589170B2 (en) 1989-10-05
NL192205C (en) 1997-03-04
IT1228241B (en) 1991-06-05
FI84268B (en) 1991-07-31
KR860008189A (en) 1986-11-12
CN86102630A (en) 1987-02-04
AU5616886A (en) 1986-11-06
GB2173798B (en) 1988-11-30
AR242581A1 (en) 1993-04-30
SG90890G (en) 1991-01-18
NO164659B (en) 1990-07-23
HUT41033A (en) 1987-03-30
FR2580652A1 (en) 1986-10-24
CS287286A2 (en) 1989-11-14
DK182486D0 (en) 1986-04-21
IE861048L (en) 1986-10-22
SE8601825D0 (en) 1986-04-21
PT82436B (en) 1988-11-30
HU195223B (en) 1988-04-28
ES554215A0 (en) 1987-10-16
LU86402A1 (en) 1986-11-05
OA08245A (en) 1987-10-30
CS270435B2 (en) 1990-06-13
AT392072B (en) 1991-01-25
ZM4286A1 (en) 1989-03-27
SE8601825L (en) 1986-10-23
ZA862985B (en) 1986-12-30
CN1015714B (en) 1992-03-04
ZW9086A1 (en) 1986-12-03
EG18001A (en) 1991-11-30
IE59014B1 (en) 1993-12-15
SU1435155A3 (en) 1988-10-30
FI861634A0 (en) 1986-04-17
GB8609661D0 (en) 1986-05-29
DE3613365C2 (en) 1989-06-15
GR861065B (en) 1986-09-01
FI84268C (en) 1991-11-11

Similar Documents

Publication Publication Date Title
US6034237A (en) 3-imino-cephalosporins
JPH0680064B2 (en) New cephem compound
MXPA96004353A (en) Sistensis de cefalospori
CZ280411B6 (en) D-2-aminoacyl-3-(z)-propenylcephalosporin derivatives, process of their preparation and pharmaceutical compositions containing thereof
CA1276929C (en) Cephalosporin antibacterial agents
GB2173798A (en) Cephalosporanic acid derivatives
EP0099553B1 (en) Cephem compounds, process and intermediates for their preparation and pharmaceutical compositions containing them
US5081116A (en) Cephalosporin derivatives
US4699979A (en) 7-amino-3-propenylcephalosporanic acid and esters thereof
GB2178032A (en) Cephalosporanic acid derivatives
GB2071664A (en) Phosphonic acid derivatives of 7-((2-amino-4- thiazolyl)oximino)cephalosporins
US4994454A (en) Cepham derivatives
US4943631A (en) Process for cephem compounds
US4699981A (en) Cephalosporin derivatives
KR870000528B1 (en) Process for preparing 3-azidocephalosporins
US3922268A (en) 3-Halomethyl-{66 {hu 3-Cephalosporin esters
US4334065A (en) Cephalosporin intermediates
US4841044A (en) Cephalosporin derivatives
GB1602876A (en) Method for producing cepham compounds
KR900004930B1 (en) Process for preparing 7-amino -3-prophenyl cephalosporins
EP0098615B1 (en) 1-oxadethiacephalosporin compound and antibacterial agent containing the same
GB2131799A (en) Cephalosporin compounds
HU205935B (en) Process for producing cepheme-derivatives
JPH01308288A (en) Novel cephem compound and production thereof
JPH01308285A (en) Beta-lactam derivative

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20060420